Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (XOMAO) SEC filings page on Stock Titan is intended to organize regulatory documents related to XOMA Royalty’s preferred stock and broader capital structure. While no specific SEC filings are listed in the provided data, XOMA Royalty’s press releases describe a business model and transaction activity that are typically reflected in formal filings such as annual reports, quarterly reports, and registration statements.
XOMA Royalty characterizes itself as a biotechnology royalty aggregator that acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. When it acquires these future economic rights, the seller receives non-dilutive, non-recourse funding. The company also explains that its portfolio consists of milestone and royalty rights associated with baskets of drug products in development, and that its assets are milestone and royalty rights tied to individual drug products.
For a security like XOMAO, which represents depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock, SEC filings are the primary source for detailed terms of the preferred stock, including dividend provisions, ranking, and any redemption or liquidation preferences. In addition, XOMA Royalty’s acquisitions of companies such as HilleVax, LAVA Therapeutics, and Mural Oncology, along with royalty sharing transactions like the amended Takeda collaboration, are the types of material events that are generally described in current reports and periodic filings.
On Stock Titan, the XOMAO filings page can be used alongside XOMA Royalty’s public press releases to understand how the company reports its royalty and milestone portfolio, commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, and the impact of corporate transactions on its financial position. AI-powered summaries can help explain lengthy filings by highlighting sections that relate to preferred stock terms, royalty and milestone accounting, and the structure of acquisitions and royalty-sharing agreements.
Investors reviewing XOMAO may look to SEC documents for details on cumulative preferred dividend obligations, the relationship between the preferred stock and common equity, and disclosures about the risks and potential variability of royalty and milestone income. Combined with the company’s own explanatory notes on how it defines “portfolio” and “assets,” these filings provide a regulatory view of XOMA Royalty’s royalty aggregation strategy and the securities it has issued, including the Series B preferred stock represented by XOMAO.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Jack L. Wyszomierski received an equity grant in the form of restricted stock units. He was awarded 3,586 RSUs, each representing one share of common stock at settlement. Following the grant, he directly holds 25,116 shares of common stock.
The 3,586 RSUs vest in equal monthly installments over 12 months from the grant date, conditioned on his continued service with the company. This compensation-related award is not an open-market purchase or sale but a stock-based incentive.
WYSZOMIERSKI JACK L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Jack L. Wyszomierski received an equity grant in the form of restricted stock units. He was awarded 3,586 RSUs, each representing one share of common stock at settlement. Following the grant, he directly holds 25,116 shares of common stock.
The 3,586 RSUs vest in equal monthly installments over 12 months from the grant date, conditioned on his continued service with the company. This compensation-related award is not an open-market purchase or sale but a stock-based incentive.
LIMBER JOSEPH M reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Joseph M. Limber received a grant of 3,586 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents one share of common stock and will vest in equal monthly installments over 12 months from the grant date, subject to his continued service.
Following the grant, Limber directly holds 12,820 shares of common stock. He also reports direct holdings of 10,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock and 20,000 Depositary Shares representing 8.375% Series B Cumulative stock.
LIMBER JOSEPH M reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Joseph M. Limber received a grant of 3,586 restricted stock units (RSUs) of common stock at no purchase price. Each RSU represents one share of common stock and will vest in equal monthly installments over 12 months from the grant date, subject to his continued service.
Following the grant, Limber directly holds 12,820 shares of common stock. He also reports direct holdings of 10,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock and 20,000 Depositary Shares representing 8.375% Series B Cumulative stock.
XOMA Royalty Corp director Natasha Hernday received an equity grant of 3,586 restricted stock units (RSUs) of common stock. The grant has a stated price of $0.00 per share and is described as a compensation-related award rather than an open-market purchase.
Each RSU converts into one share of XOMA common stock upon settlement and will vest in equal monthly installments over 12 months from the grant date, contingent on Hernday’s continued service. Following this grant, she directly holds 12,592 shares of common stock and 4,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock.
XOMA Royalty Corp director Natasha Hernday received an equity grant of 3,586 restricted stock units (RSUs) of common stock. The grant has a stated price of $0.00 per share and is described as a compensation-related award rather than an open-market purchase.
Each RSU converts into one share of XOMA common stock upon settlement and will vest in equal monthly installments over 12 months from the grant date, contingent on Hernday’s continued service. Following this grant, she directly holds 12,592 shares of common stock and 4,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock.
XOMA Royalty Corp director Matthew D. Perry received a grant of 3,586 restricted stock units (RSUs) of common stock at no cost. Each RSU converts into one share and will vest in equal monthly installments over 12 months, contingent on his continued service. Following this equity award, he directly owns 27,426 shares of XOMA common stock.
XOMA Royalty Corp director Matthew D. Perry received a grant of 3,586 restricted stock units (RSUs) of common stock at no cost. Each RSU converts into one share and will vest in equal monthly installments over 12 months, contingent on his continued service. Following this equity award, he directly owns 27,426 shares of XOMA common stock.
Franklin Heather L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Heather L. Franklin received a grant of 3,586 restricted stock units (RSUs) of common stock on May 21, 2026. The award was made at no cash cost per share as part of equity compensation. Each RSU represents the right to receive one share of XOMA common stock at settlement and will vest in equal monthly installments over 12 months, subject to her continued service with the company. Following this grant, Franklin directly owns 9,557 shares of common stock, reflecting a modest, routine increase in her equity stake through compensation rather than open‑market buying.
Franklin Heather L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Heather L. Franklin received a grant of 3,586 restricted stock units (RSUs) of common stock on May 21, 2026. The award was made at no cash cost per share as part of equity compensation. Each RSU represents the right to receive one share of XOMA common stock at settlement and will vest in equal monthly installments over 12 months, subject to her continued service with the company. Following this grant, Franklin directly owns 9,557 shares of common stock, reflecting a modest, routine increase in her equity stake through compensation rather than open‑market buying.
Kosacz Barbara reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Barbara Kosacz received a grant of 3,586 restricted stock units (RSUs) of common stock. The RSUs were awarded at no cash cost per unit and will vest in equal monthly installments over 12 months, conditioned on her continued service to the company. Following this equity award, she holds 9,557 shares of common stock directly.
Kosacz Barbara reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Barbara Kosacz received a grant of 3,586 restricted stock units (RSUs) of common stock. The RSUs were awarded at no cash cost per unit and will vest in equal monthly installments over 12 months, conditioned on her continued service to the company. Following this equity award, she holds 9,557 shares of common stock directly.
XOMA Royalty Corporation reported the results of its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan, adding 425,000 shares of common stock for equity awards and extending the plan’s term to March 16, 2036.
They also approved the 2026 Employee Stock Purchase Plan, making 500,000 shares available for employee purchases, and ratified Deloitte & Touche LLP as independent auditor. All director nominees were elected and the advisory vote on executive compensation passed. As part of a previously announced merger process, the board adopted bylaw amendments addressing Nevada controlling interest statutes and adding exclusive forum provisions.
XOMA Royalty Corporation reported the results of its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan, adding 425,000 shares of common stock for equity awards and extending the plan’s term to March 16, 2036.
They also approved the 2026 Employee Stock Purchase Plan, making 500,000 shares available for employee purchases, and ratified Deloitte & Touche LLP as independent auditor. All director nominees were elected and the advisory vote on executive compensation passed. As part of a previously announced merger process, the board adopted bylaw amendments addressing Nevada controlling interest statutes and adding exclusive forum provisions.
XOMA Royalty Corp large shareholders affiliated with Biotechnology Value Fund converted Series X Convertible Preferred Stock into common stock. On May 14, 2026, entities in the reporting group converted a total of 5,003 shares of Series X Preferred into 5,003,000 shares of common stock at a $4.03 per share conversion price. After these conversions, the Form 4 shows only common stock positions, with the Series X Preferred balances reduced to zero for the reporting entities involved. The transactions are reported as exempt from short-swing profit rules under Rule 16b-6(b) and reflect changes in the form of ownership rather than open-market buying or selling.
XOMA Royalty Corp large shareholders affiliated with Biotechnology Value Fund converted Series X Convertible Preferred Stock into common stock. On May 14, 2026, entities in the reporting group converted a total of 5,003 shares of Series X Preferred into 5,003,000 shares of common stock at a $4.03 per share conversion price. After these conversions, the Form 4 shows only common stock positions, with the Series X Preferred balances reduced to zero for the reporting entities involved. The transactions are reported as exempt from short-swing profit rules under Rule 16b-6(b) and reflect changes in the form of ownership rather than open-market buying or selling.
BVF Partners and affiliated funds report a 43.3% stake in XOMA Royalty Corp following conversion of preferred shares. The group now beneficially owns 7,593,303 common shares, calculated using 12,541,030 shares outstanding as of May 7, 2026 plus 5,003,000 shares received in a "Series X Conversion."
On May 14, 2026 the reporting persons increased the Series X Beneficial Ownership Limitation to 45% and converted all their Series X Preferred Stock into common shares at a conversion price of $4.03 per share. BVF, BVF2, Trading Fund OS and managed accounts together invested roughly $44.1 million in the converted and other purchased shares.
BVF Partners and affiliated funds report a 43.3% stake in XOMA Royalty Corp following conversion of preferred shares. The group now beneficially owns 7,593,303 common shares, calculated using 12,541,030 shares outstanding as of May 7, 2026 plus 5,003,000 shares received in a "Series X Conversion."
On May 14, 2026 the reporting persons increased the Series X Beneficial Ownership Limitation to 45% and converted all their Series X Preferred Stock into common shares at a conversion price of $4.03 per share. BVF, BVF2, Trading Fund OS and managed accounts together invested roughly $44.1 million in the converted and other purchased shares.
XOMA Royalty Corporation filed an update on its pending acquisition by Ligand Pharmaceuticals. On May 16, 2026, XOMA Royalty, Ligand, Flex Merger Sub and a newly formed subsidiary, XOMA Royalty Holdings Corporation (HoldCo), entered into Amendment No. 1 to their Agreement and Plan of Merger, formally adding HoldCo as a party.
HoldCo is a wholly owned subsidiary created to implement a holding company reorganization under Nevada law before Merger Sub combines with HoldCo, which will then become a wholly owned subsidiary of Ligand. The filing emphasizes that detailed terms and potential impacts will be described in preliminary and definitive proxy statements that XOMA Royalty plans to file, and urges stockholders to review those materials before voting on the proposed acquisition.
XOMA Royalty Corporation filed an update on its pending acquisition by Ligand Pharmaceuticals. On May 16, 2026, XOMA Royalty, Ligand, Flex Merger Sub and a newly formed subsidiary, XOMA Royalty Holdings Corporation (HoldCo), entered into Amendment No. 1 to their Agreement and Plan of Merger, formally adding HoldCo as a party.
HoldCo is a wholly owned subsidiary created to implement a holding company reorganization under Nevada law before Merger Sub combines with HoldCo, which will then become a wholly owned subsidiary of Ligand. The filing emphasizes that detailed terms and potential impacts will be described in preliminary and definitive proxy statements that XOMA Royalty plans to file, and urges stockholders to review those materials before voting on the proposed acquisition.